TITLE

Clinical Potential of Emerging New Agents in Hepatitis B

AUTHOR(S)
Farrell, G.C.
PUB. DATE
October 2000
SOURCE
Drugs;Oct2000, Vol. 60 Issue 4, p701
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Treatment of chronic hepatitis B is directed at interrupting the natural history and clinical outcomes of the disease. It needs to take into account the virology and replication cycle of the hepatitis B virus (HBV), and the host immune response to HBV. Long term follow-up of patients treated with interferon supports the paradigm that a sustained, major suppression of HBV replication, particularly that associated with hepatitis B e antigen (HBeAg) seroconversion, interrupts the natural history of hepatitis B. The availability of potent but well tolerated and orally available HBV antivirals, of which lamivudine is the prototype, has allowed clearer treatment objectives to be formulated. These are: temporary or permanent reduction of hepatitis (necroinflammatory) activity, arrest of fibrotic progression, prevention of cirrhosis and liver failure, and prevention of recurrent HBV infection after liver transplantation. Lamivudine has good medium term efficacy in achieving each of these objectives. The only significant problem for the longer term is emergence of antiviral resistance conferred by mutations in the YMDD (tyrosine-methionine-aspartic acid-aspartic acid) motif of the HBV reverse transcriptase. As a result, contentious issues remain about defining when antiviral therapy is indicated, whether to treat for a defined interval or indefinitely, and when to stop treatment if HBeAg seroconversion is not achieved. Some personal views are expressed in this review. Among newer HBV antivirals in clinical studies, adefovir dipivoxil, entecavir and emtricitabine appear to be at least as potent as lamivudine in suppressing HBV replication. Famciclovir appears less potent. In vitro studies show that YMDD mutations confer cross-resistance between lamivudine, emtricitabine and β-L-Fd4C (L-2′,3′-didehydro-dideoxy-5-fluorocytidine). However, adefovir dipivoxil, lobucavir, entecavir, DAPD (β-D-2,6-diaminopurine dioxolane) and possibly clevudine (L-FMAU) suppress replication of YMDD mutant HBV, as well as wildtype. Preliminary studies indicate clinical efficacy of adefovir dipivoxil once resistance to lamivudine has developed. Immunomodulatory approaches to treatment of chronic hepatitis B are conceptually attractive, but newer agents used to date (thymalfasin, interleukin-12, therapeutic vaccines) have not demonstrated sufficient efficacy for widespread use. The next challenge for HBV treatment is to use antivirals in combination and/or in cyclical therapy to reduce the emergence of drug resistance and increase efficacy, particularly to achieve sustainable post-treatment suppression of hepatitis B.
ACCESSION #
9593320

 

Related Articles

  • Comparison of the accelerated and classic vaccination schedules against Hepatitis B: three-week Hepatitis B vaccination schedule provides immediate and protective immunity. Saltoğlu, Nese; Inal, A. Seza; Tasova, Yesim; Kandemir, Ozlem // Annals of Clinical Microbiology & Antimicrobials;2003, Vol. 2, p10 

    Background: Hepatitis B virus infection although preventable by vaccination remains an important health issue throughout the world due to its morbidity, mortality and economical losses. Early seroprotection is desirable for people at high risk of exposure. The aim of this study was to determine...

  • B7-DC-silenced dendritic cells induce stronger anti-HBV immunity in transgenic mice. Yan Fan; Wen-Zheng Jiang; Jie-Jun Wen; Wen-Li Hao; Jia-Ni Du; Xia Liu; Min Qian // Archives of Virology;Nov2009, Vol. 154 Issue 11, p1813 

    Hepatitis B virus (HBV) is a noncytopathic DNA virus and is the pathogen of acute and chronic hepatitis. Interferon and nucleotide analogues such as lamivudine and adefovir are the current treatment strategies of HBV infection; however, it is still a serious disease. Therefore, the development...

  • Combinatorial analysis and algorithms for quasispecies reconstruction using next-generation sequencing. Prosperi, Mattia C. F.; Prosperi, Luciano; Alessandro Bruselles; Abbate, Isabella; Rozera, Gabriella; Vincenti, Donatella; Solmone, Maria Carmela; Capobianchi, Maria Rosaria; Ulivi, Giovanni // BMC Bioinformatics;2011, Vol. 12 Issue 1, p1 

    Background: Next-generation sequencing (NGS) offers a unique opportunity for high-throughput genomics and has potential to replace Sanger sequencing in many fields, including de-novo sequencing, re-sequencing, metagenomics, and characterisation of infectious pathogens, such as viral...

  • Development of Real-Time PCR Array for Simultaneous Detection of Eight Human Blood-Borne Viral Pathogens. Pripuzova, Natalia; Wang, Richard; Shien Tsai; Bingjie Li; Guo-Chiuan Hung; Ptak, Roger G.; Shyh-Ching Lo; Chiyu Zhang // PLoS ONE;Aug2012, Vol. 7 Issue 8, Special section p1 

    Background:Real-time PCR array for rapid detection of multiple viral pathogens should be highly useful in cases where the sample volume and the time of testing are limited, i.e. in the eligibility testing of tissue and organ donors. Findings:We developed a real-time PCR array capable of...

  • Fitoterapia de la hepatitis viral B crónica. RUIZ, LUIS HUACUJA; VELÁZQUEZ, ALMA LORENA LÓPEZ; PANDURO, ARTURO; MONDRAGÓN, PEDRO; BELTRÁN, MARIA DE LA LUZ MIRANDA // Investigación en Salud;dic2007, Vol. 9 Issue 3, p190 

    The pharmacological treatments for the HBV in general they have not been successful on viral activity because of its low answer, long treatments produce drug resistance and occasionally adverse effects. Due to these complications has become more attractive the use of medicinal plants using the...

  • Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B.  // Clinical Infectious Diseases;3/15/2003, Vol. 36 Issue 6, p687 

    YMDD variants of hepatitis B virus (HBV) emerge in some patients with chronic hepatitis B who receive lamivudine. YMDD variants were examined in 794 patients in 4 controlled studies of 1 year's duration. The long-term effects of YMDD variants were examined in a subset of patients treated up to 4...

  • Molecular Therapeutics of HBV. Ruian Xu; Kexia Cai; Dexian Zheng; Hong Ma; Sue Xu; Sheung-tat Fan // Current Gene Therapy;Aug2003, Vol. 3 Issue 4, p341 

    The hepatitis B virus (HBV) infection is a public health problem worldwide, particularly in East Asia. The current therapy of HBV infection is mostly based on chemical agents and cytokines that have been shown to provide limited efficacy and are also toxic to the human body. Gene therapy is a...

  • Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. F. Moriconi; P. Colombatto; B. Coco; P. Ciccorossi; F. Oliveri; D. Flichman; A. M. Maina; R. Sacco; F. Bonino; M. R. Brunetto // Journal of Antimicrobial Chemotherapy (JAC);Aug2007, Vol. 60 Issue 2, p341 

    Objectives We studied the impact of hepatitis B virus (HBV) polymerase/reverse transcriptase (Pol/Rt) heterogeneity on adefovir rescue therapy in 34 consecutive chronic hepatitis B patients with viral breakthrough during lamivudine monotherapy. Methods The Pol/Rt A–F domains were...

  • Comparison of 12-Month Courses of Interferon-α -2b--Lamivudine Combination Therapy and Interferon-α -2b Monotherapy among Patients with Untreated Chronic Hepatitis B. Yalcin, Kendal; Degertekin, Halil; Yildiz, Fetin; Celik, Yusuf // Clinical Infectious Diseases;6/15/2003, Vol. 36 Issue 12, p1516 

    We compared the use of prolonged synchronous combination therapy with interferon (IFN)-α-2b and lami-vudine with the use of IFN-α-2b monotherapy in patients with untreated hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection. Thirty-three patients received...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics